|3Aug 9, 6:32 PM ET

Antibody Investments LLC 3

3 · VACCINEX, INC. · Filed Aug 9, 2018

Insider Transaction Report

Form 3
Period: 2018-08-09
Holdings
  • Series C Convertible Preferred Stock

    Common Stock (1,346,139 underlying)
  • Series D Convertible Preferred Stock

    Common Stock (549,444 underlying)
Footnotes (2)
  • [F1]The reported securities will convert into shares of Common Stock on a 0.1868-for-1 basis immediately prior to the consummation of the Issuer's initial public offering.
  • [F2]The reported securities will convert into shares of Common Stock on a 1-for-10 basis immediately prior to the consummation of the Issuer's initial public offering.

Documents

1 file
  • 3
    edgar.xmlPrimary

    PRIMARY DOCUMENT